ASSESSMENT OF RELATED ANAMNESTIC AND CLINICAL FACTORS ON EFFICACY AND SAFETY OF ANTI-HELICOBACTER PYLORI THERAPY
https://doi.org/10.20514/2226-6704-2016-6-1-29-33
Abstract
The article presents the results of a prospective clinical study in which 100 patients with H. pylori-associated peptic ulcer disease of stomach/duodenum were examined. The aim of the study was to assess the effect of concomitant anamnestic and clinical factors on the efficacy and safety of eradication therapy (ET). Type 2 diabetes mellitus is a factor that significantly reduces the efficiency of ET with OR 0.21 (95% CI 0,06-0,69, p = 0,0102). Using a macrolide antibiotics prior to ET during the previous 12 months is associated with a reduction in the effectiveness of H. pylori eradication with OR 0.27 (95% CI 0,08-0,90, p = 0,0342). Despite the lack of statistical significance observed negative effect on the efficiency of ET factors such as smoking and increased BMI. Smoking, female gender, age over 50 years and the presence of type 2 diabetes mellitus had no significant impact on the safety profile of ET.
About the Authors
D. N. Andreev
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow, Russia
Russian Federation
Russian Federation
I. V. Maev
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow, Russia
Russian Federation
Russian Federation
Yu. A. Kucheryavyy
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow, Russia
Russian Federation
Russian Federation
D. T. Dicheva
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow, Russia
Russian Federation
Russian Federation
References
1. Maev I.V., Andreev D.N., Kucheryavyi Yu.A. Helicobacter pylori infection and extragastroduodenal diseases. Ter Arkh. 2015;87(8):103-110.
2. Maev I.V., Kucheriavyĭ Iu.A., Andreev D.N., Barkalova E.V. Eradication therapy for Helicobacter pylori infection: review of world trends. Ter Arkh. 2014;86(3):94-99.
3. Maev I.V., Samsonov A.A., Andreev D.N. Diseases of the stomach. M.: GEOTAR-Media; 2015, 976 pp.
4. Maev I.V., Samsonov A.A., Andreev D.N. Helicobacter pylori infection. M.: GEOTAR-Media; 2016, 256 pp.
5. Mkrtumyan A.M., Kazyulin A.N., Bairova K.I. Incidence and graveness of helicobacter infection in patients with type 2 diabetes mellitus. Sakhar. Diabet. 2010; 1: 77–79.
6. Abdullahi M., Annibale B., Capoccia D. et al. The eradication of Helicobacter pylori is affected by body mass index (BMI). Obes. Surg. 2008; 11: 1450–1454.
7. Almeida N., Donato M.M., Romãozinho J.M. et al. Beyond Maastricht IV: are standard empiric triple therapies for Helicobacter pylori still useful in a South-European country? BMC Gastroenterol. 2015; 15: 23.
8. Boyanova L., Ilieva J., Gergova G. et al. Numerous risk factors for Helicobacter pylori antibiotic resistance revealed by extended anamnesis: a Bulgarian study. J Med Microbiol. 2012; 61(Pt 1): 85-93.
9. Draganov V., Nikolov R., Lazarov S. Macrolides: pharmacology and clinical use. Vutr Boles. 2000; 32(4): 13-7.
10. Freeman J.S., Gross B. Potential drug interactions associated with treatments for type 2 diabetes and its comorbidities: a clinical pharmacology review. Expert Rev Clin Pharmacol. 2012; 5(1): 31-42.
11. Gasbarrini A., Ojetti V., Pitocco D. et al. Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulindependent diabetes mellitus. Scand. J. Gastroenterol. 2000; 35: 260–263.
12. Liou J.M., Chang C.Y., Chen M.J. et al. The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors-A Nationwide Study. PLoS One. 2015; 10(5): e0124199.
13. Maev I.V., Andreev D.N., Kucheryavyi Yu.A., Dicheva D.T. Host factors influencing the eradication rate of Helicobacter pylori. World Applied Sci J. 2014; 30: 134-140.
14. Malfertheiner P., Megraud F., O’Morain C. et al. Management of Helicobacter pylori infection – Maastricht IV / Florence Consensus Report. Gut. 2012; 61: 646–664.
15. Megraud F., Coenen S., Versporten A. et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013; 62: 34–42.
16. Morgan D.R, Crowe S.E. Helicobacter pylori infection. In.: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management / edited by Mark Feldman, Lawrence S Friedman, Laurence J Brandt. – 10th ed. 2015: 856-884.
17. Sargýn M., Uygur-Bayramicli O., Sargýn H. et al. Type 2 diabetes mellitus affects eradication rate of Helicobacter pylori. World J. Gastroenterol. 2003; 9: 1126–1128.
18. Sugimoto M., Furuta T., Yamaoka Y. Influence of inflammatory cytokine polymorphisms on eradication rates of Helicobacter pylori. J. Gastroenterol. Hepatol. 2009; 24: 1725–1732.
19. Suzuki T., Matsuo K., Ito H. et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am. J. Med. 2006; 119: 217–224.
20. Triplitt C. Drug Interactions of Medications Commonly Used in Diabetes. Diabetes Spectrum. 2006; 19(4): 202-210.
21. Uotani T., Miftahussurur M., Yamaoka Y. Effect of bacterial and host factors on Helicobacter pylori eradication therapy. Expert Opin Ther Targets. 2015; 19(12): 1637-50.
22. Wu W., Yang Y., Sun G. Recent insights into antibiotic resistance in Helicobacter pylori eradication. Gastroenterol. Res. Pract. 2012. Article ID 723183.
Review
For citations:
Andreev D.N., Maev I.V., Kucheryavyy Yu.A., Dicheva D.T. ASSESSMENT OF RELATED ANAMNESTIC AND CLINICAL FACTORS ON EFFICACY AND SAFETY OF ANTI-HELICOBACTER PYLORI THERAPY. The Russian Archives of Internal Medicine. 2016;6(1):29-33. (In Russ.) https://doi.org/10.20514/2226-6704-2016-6-1-29-33
Views:
996
Email this article 